DIFLUCAN 150mg Rx
Generic Name and Formulations:
Fluconazole 150mg; tabs.
Indications for DIFLUCAN 150mg:
150mg orally once.
Concomitant terfenadine at multiple doses of fluconazole ≥400mg. Concomitant drugs known to prolong the QT interval and metabolized by CYP3A4 (eg, cisapride, astemizole, erythromycin, pimozide, quinidine).
Proarrhythmic conditions. Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Risk of cardiotoxicity with erythromycin; avoid. Avoid concomitant voriconazole; if needed, monitor closely esp. when given within 24hrs after fluconazole. Potentiates warfarin, oral hypoglycemics, oral midazolam, tofacitinib, alfentanil, amitriptyline, nortriptyline, calcium channel blockers, losartan, saquinavir; adjust dose as necessary. May increase serum levels of phenytoin, theophylline, halofantrine, rifabutin, tacrolimus, sirolimus, vinca alkaloids, triazolam, methadone, NSAIDs, cyclosporine, zidovudine, sulfonylureas, carbamazepine. Concomitant celecoxib: reduce celecoxib dose by half. Thiazides increase fluconazole levels. Monitor levels and/or effects of cyclosporine, phenytoin, sulfonylureas, rifabutin, tacrolimus, theophylline, warfarin, prednisone. Increased risk of myopathy/rhabdomyolysis with concomitant HMG-CoA reductase inhibitors; closely monitor. Cimetidine (oral), rifampin may decrease fluconazole levels. Oral contraceptives: see full labeling. Avoid other hepatotoxic drugs. Caution with other drugs metabolized by CYP2C9 and CYP3A4 with a narrow therapeutic window.
Nausea, headache, rash, vomiting, abdominal pain, diarrhea, dizziness, seizures; hepatotoxicity; rare: exfoliative dermatitis, QT prolongation, Torsade de pointes.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
- Anticancer Properties of The Probiotic Kefir: A Review
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma
- Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|